Louisiana 2025 Regular Session

Louisiana Senate Bill SB19

Introduced
3/24/25  
Refer
3/24/25  
Refer
4/14/25  
Report Pass
4/28/25  
Engrossed
5/5/25  
Refer
5/6/25  
Report Pass
5/28/25  

Caption

Provides relative to the dispensing of ivermectin. (gov sig)

Impact

The enactment of SB19 is likely to impact state laws by formalizing the role of pharmacists in dispensing ivermectin, which may lead to increased accessibility of the drug for eligible patients. This bill supports the pharmacists’ initiative to play a more proactive role in patient healthcare, especially in circumstances where immediate access to medication is needed without a prior personal visit to a healthcare provider. This can have significant implications for public health strategies and management of specific conditions treated with ivermectin.

Summary

Senate Bill 19 (SB19) establishes new regulations for the dispensing of ivermectin in Louisiana. Under this bill, pharmacists are authorized to dispense ivermectin to individuals aged eighteen and older based on a standing order issued by a qualified healthcare professional from the Louisiana Department of Health. The bill outlines specific protocols, including the requirement for pharmacists to provide patients with a screening risk assessment tool and necessary information related to the use of ivermectin, highlighting the importance of medical follow-up.

Sentiment

The sentiment surrounding SB19 appears to be largely supportive from the healthcare and pharmacy communities, as many see it as a necessary step toward modernizing the dispensing process for common medications. However, there might be some undercurrents of contention related to the lack of requirements for health insurance to cover the costs associated with ivermectin, which could lead to debates around healthcare accessibility and affordability for patients requiring this medication.

Contention

One notable point of contention with SB19 is its provision that pharmacists will be immune from civil liability when acting in good faith under this legislation, which raises concerns about accountability and quality assurance in drug dispensing. While this immunity is intended to protect pharmacists, critics may argue it could lead to potential risks in patient safety and undermine the responsibility of healthcare providers in administering treatments. This aspect may cause friction among various stakeholders in the healthcare system as they navigate the implications of such legal protection.

Companion Bills

No companion bills found.

Similar Bills

MS HB1288

Ivermectin; authorize pharmacists to provide to adults pursuant to collaborative pharmacy practice agreement.

MS HB1300

Ivermectin; authorize pharmacists to provide to adults pursuant to collaborative pharmacy practice agreement.

MS HB1511

Ivermectin; authorize pharmacists to provide to adults pursuant to collaborative pharmacy practice agreement.

LA HB312

Provides relative to the over-the-counter sale and purchase of the drug ivermectin without a prescription

NH HB1022

Permitting pharmacists to dispense the drug Ivermectin by means of a standing order and establishing a commission to study the use of Ivermectin to treat Covid-19.

WV SB614

Authorizing over-the-counter sale of Ivermectin

AL HB278

Pharmacists, allow to dispense ivermectin without a prescription

AL HB499

Relating to prescription drugs; to provide for the dispensing of Ivermectin by a pharmacist without an individual prescription pursuant to a standing order issued by a physician, physician's assistant, or certified registered nurse practitioner; to protect physicians, physician's assistants, certified registered nurse practitioners, and pharmacists from licensure disciplinary action due to dispensing Ivermectin.